
Lexeo Therapeutics Investor Relations Material
Latest events

Study Update
Lexeo Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Lexeo Therapeutics Inc
Access all reports
Lexeo Therapeutics Inc. operates as a clinical-stage genetic medicine company focused on hereditary and acquired diseases. The company is advancing a portfolio of gene therapy candidates, including LX2006 for Friedreich's ataxia cardiomyopathy, LX2020 for arrhythmogenic cardiomyopathy, LX2021 for DSP cardiomyopathy, and LX2022 for hypertrophic cardiomyopathy caused by TNNI3 mutations. Additionally, Lexeo Therapeutics is developing therapies for APOE4 homozygous conditions and CLN2 Batten disease, among others, utilizing its AAVrh10-based gene therapy platform. The company is headquartered in New York, New York, and its shares are listed on the Nasdaq.
Key slides for Lexeo Therapeutics Inc


Corporate Presentation
Lexeo Therapeutics Inc


Corporate Presentation
Lexeo Therapeutics Inc
Latest articles
)
James Quincey: Coca-Cola Chairman and CEO
James Quincey has dedicated nearly three decades to The Coca-Cola Company, rising through the ranks to become CEO and Chairman of the company.
11 Mar 2025
)
PepsiCo: From Pepsi and Gatorade to Doritos and Lay's
PepsiCo has grown from a soda company into a global leader in food and beverages, with a portfolio of over 200 brands, including Pepsi, Lay's, and Gatorade.
11 Mar 2025
)
Bob Iger: Disney's Visionary CEO
Bob Iger is a legend in the entertainment industry, known for his visionary leadership and as one of the most influential CEOs in Disney's history.
10 Mar 2025
Ticker symbol
LXEO
Country
🇺🇸 United States